Navigation Links
DNA test could be key to targeting treatments for head and neck cancer
Date:10/5/2009

It is estimated that more than 7,000 people are diagnosed with head and neck cancer each year in the UK and approximately 3,500 cases result in death. These cancers include tumours of the mouth, lips, throat and voice-box, and some have been linked to the sexually transmitted infection, HPV-16. Scientists at Liverpool analysed the DNA of more than 90 cancerous tissue samples to look for genes that indicated infection.

The team found that nearly two thirds of tonsil tumour samples showed evidence of the HPV-16 gene. It is thought that chemical alterations in the virus's DNA trigger the production of proteins that can alter the rate at which cells grow and repair. This strongly increases the possibility of subsequent cancer development. Recent studies have found, however, that patients who have the HPV infection when they are diagnosed with cancer, respond better to chemotherapy or radiation therapy than those that do not have the infection. The work will be presented at the National Cancer Research Institute's (NCRI) Cancer Conference in Birmingham today.

Mr Richard Shaw, from the School of Cancer Studies, explains: "Recent evidence demonstrates the possible involvement of HPV in the development of tonsil cancer, particularly in non-smokers. Interestingly, the treatment efficiency of chemotherapy and radiation, seems to differ between HPV positive and negative cases. We also need to find out why only a small percentage of people with this common infection develop this cancer. Our study, however, gives us a new lead towards a risk marker.

"It is thought that HPV interacts in the cell with genes controlling the chemical modification of DNA, which affects gene expression and tumour behaviour. Our study shows that HPV may be a trigger of tonsil cancer, independent of the known common causes, such as smoking or drinking. The work also suggests that a DNA test to determine the activity of HPV, could be used to identify the most
'/>"/>

Contact: Samantha Martin
samantha.martin@liv.ac.uk
01-517-942-248
University of Liverpool
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Swine Flu Tests Could Swamp Diagnostic Labs
2. Swine Flu Could Create Hospital Bed Shortage
3. Could the Recession Be Good for Your Health?
4. UCLA study identifies 2 chemicals that could lead to new drugs for genetic disorders
5. Van Andel Institute researchers find gene that could lead to new therapies for bone marrow disease
6. MIT retinal implant could help restore some vision
7. Swine flu could wreak more havoc on US economy, says UAB economist
8. Discovery could improve hepatitis C treatment
9. Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients
10. Could Swine Flu Panic Be Worse Than Outbreak Itself?
11. New device could more effectively alleviate menstrual cramp pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 2014 Secura Consultants, based in ... marketing organizations in the country focused on delivering ... marketplace. Secura Consultants is proud to offer complimentary ... Group, a leading global financial company. , Many ... the ownership interest comes the need for business ...
(Date:11/28/2014)... Alex Kramer HealthDay ... Getting kids involved in the kitchen, through cooking classes or ... foods, according to a recent review. Cooking programs and ... and behaviors, according to the new research. And, although the ... findings suggest that such programs might help children develop long-lasting ...
(Date:11/28/2014)... CA (PRWEB) November 28, 2014 ... online, reported during the hugely popular, 2014 MTV ... antismoking organization Truth launched ground-breaking celebrity centered television ... The MTV viewership figures were estimated by ... antismoking ads placed the spotlight on celebrities photographed ...
(Date:11/28/2014)... UniWigs.com, a leader in the wig industry, has announced ... next Monday. This promotion features: , > 400 ... to 70% off (no coupon code needed), > ... on orders over $49 , Visit http://www.uniwigs.com for more ... 28th to Dec. 1st and the first 100 shoppers each day ...
(Date:11/28/2014)... An inventor from Flint, Mich., wants to minimize the trouble ... while lying in a hospital bed, unable to get up ... Buddy provides a more ergonomic and convenient way for a ... need to leave the bed, which avoids hassle and strain, ... and producible in design variations, it's ideal for elderly and/or ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2
... today announced the,expansion of its proprietary pipeline, with ... orally-available small molecule compound,targeted for the treatment of ... inhibit major signalling pathways,involving Flt3 and CDK, which ... the most frequent genetic alterations,reported in acute myeloid ...
... NEWTOWN SQUARE, Pa., Nov. 27 In its ... homeopathy, Boiron,Laboratories disputes an editorial comment published in ... that its author has misinterpreted results of,clinical trials ... journal features an editorial by Ben Goldacre on,the ...
... say current labeling doesn,t reflect reports of bizarre behaviors ... (HealthDay News) -- A U.S. Food and Drug Administration ... Tamiflu (oseltamivir) should have a stronger warning label to ... who use the medication. , The FDA,s Pediatric Advisory ...
... ZMH ; SWX: ZMH) today announced that J. ... a member of the Board of Directors effective,November 30, ... John L.,McGoldrick, a current Board member, will serve as ... and Chief Executive Officer,of the Company from August 2001 ...
... Pronounced "mursa,",methicillin-resistant staphylococcus aureus (MRSA) is one of the ... it. It has,killed the elderly, babies, toddlers, teenagers and ... public schools., One of the most common places ... can start innocently, perhaps with a nick or cut. ...
... Rate..., CLEARWATER, Fla., Nov. 27 minSURG Corporation, ... it has certified over 600 surgeons in its TruFUSE ... in the basic technique at the,North American Spine Society ... believe that this milestone is a reasonable predictor that ...
Cached Medicine News:Health News:S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 3Health News:FDA Panel Backs Tougher Warning for Tamiflu 2Health News:FDA Panel Backs Tougher Warning for Tamiflu 3Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 2Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 3Health News:New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Family's Feet 2Health News:Over 600 Surgeons Certified to use TruFUSE(R) to Treat Back Pain Sufferers 2
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... , Nov. 26, 2014 The medical ... a rate of 4%, with world market revenues ... Information. MRI and other types of medical imaging ... treatment of numerous medical conditions in children and ... techniques. Kalorama,s report, Medical Imaging Markets , ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , a pharmaceutical ... of cancer, today announced that the University of ... institution, has successfully completed the first cohort in ... trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging ...
... 2012 HIGHLIGHTS :2012 Results (all ... Q1 2012 reported sales increased 5% to $665 million, a new ... Fine Chemicals ("SAFC") organic sales growth of 4% and 1%, respectively.  ... exchange rates reduced otherwise reportable sales by 2%. , ...
Cached Medicine Technology:Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 2Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 3Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 4Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 2Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 3Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 4Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 6Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 7Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 8Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 9Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 10Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 11Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 12Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 13
PremierEdge™ Stab Knives - 15°....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 2.0mm....
Medicine Products: